Reliance Life Sciences provides clinical research services, regenerative medicine, and specialty pharmaceuticals. Self-described as a global biopharmaceutical business based in India, it offers a complete range of services for clinical development of molecules and is involved in high-end DNA-based diagnostic testing.

Reliance Life Sciences

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

BeiGene, Ltd.

BioReliance offers contract testing services specializing in analytical and biosafety testing, supporting the development of biologics from pre-clinical stages to licensed production. It provides expertise in biologics safety testing, analytical development, and biomanufacturing services.

BioReliance

Elektrofi is a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic therapies through subcutaneous administration.

Metric
Company Name	Reliance Life Sciences	BeiGene, Ltd.	BioReliance	Elektrofi
Symbol		BGNE
MSH ID	COM:RELLIFE	COM:BEIGENE	COM:BIORELIANCE	COM:ELEKTROFI
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biopharmaceutical
Country	IN	US	US	US
Stage
Employee Count		10K
Website	rellife.com	beigene.com	bioreliance.com	elektrofi.com
LinkedIn
Founders

Metric
Market Cap		15.82B
Enterprise Value
Monthly Web Traffic	17.18K
Web Traffic Growth	0.08
Valuation
Raised Capital

Metric
Revenue		2.46B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.99B
EBITDA		-1.12B
Operating Income		-1.21B
Net Income		-881.71M
EPS		-8.45
Diluted EPS		-8.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.84
Operating Profit Margin		-0.29
EBITDA Margin		-0.46
Net Profit Margin		-0.17
Return on Equity		-0.15
Return on Assets		-0.09
Return on Capital Employed		-0.23

RELL

COM:RELLIFE

Reliance Life Sciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-20.11
P/B Ratio		5.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		8.97
EV Multiple		-16.29

Metric
Days Sales Outstanding		58.72
Days Payables Outstanding		102.58
Days Inventory Outstanding		331.60
Operating Cycle		394.01
Cash Conversion Cycle		147.98
Asset Turnover		0.54

Metric
Operating Cash Flow		-1.16B
Free Cash Flow		-1.74B
Cash Flow to Debt		-0.56
Operating Cash Flow/Sales		-0.20
Free Cash Flow Yield		-0.13

Metric
Cash & Equivalents		3.18B
Accounts Receivable		-188.31M
Inventory		416.12M
Goodwill
Debt to Capitalization		0.24
Debt to Assets		0.10
Current Ratio		3.16
Quick Ratio		1.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.16
R&D to Revenue		1.16
SG&A to Revenue